Serum uric acid trajectories and risk of metabolic dysfunction-associated steatotic liver disease in China: a 2019-2021 cohort health survey

被引:0
作者
Shi, Dan [1 ]
Tan, Qilong [2 ,3 ]
Zhang, Yong [1 ,4 ]
Qi, Xiaoya [4 ]
Xu, Xiaoyang [4 ]
Xu, Guoqiong [4 ]
Bai, Ruixue [4 ]
Deng, Jing [4 ]
Chen, Mengxue [4 ]
Jiang, Tao [4 ]
Mei, Ying [4 ]
机构
[1] Chongqing Med Univ, Sch Publ Hlth, Chongqing 400016, Peoples R China
[2] Zhejiang Univ, Sch Publ Hlth, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China
[3] Harbin Med Univ, Sch Publ Hlth, Harbin 150081, Heilongjiang, Peoples R China
[4] Chongqing Med Univ, Hosp 2, Dept Hlth Management, Chongqing 400011, Peoples R China
关键词
MASLD; Uric acid; Trajectory; China; FATTY LIVER; HEPATIC STEATOSIS; HYPERURICEMIA; HYPERTENSION; GENERATION; STRESS;
D O I
10.1186/s12889-024-21214-0
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
ObjectiveTo investigate the associations between serum uric acid (UA) trajectories and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in large cohort survey 2019-2021.MethodsThis cohort health survey included 11,644 participants without MASLD before January 1, 2021. Among them, 5578 (47.90%) were men and 6066 (52.10%) were women. The group-based trajectory model method was applied to identify serum UA trajectories from January 1, 2019, to December 30, 2021. New-onset MASLD events in 2021 were treated as outcomes. A logistic regression model was used to assess associations between UA trajectories and incidence of MASLD.ResultsFour distinct serum UA trajectories among both sexes were identified: "low-stable" trajectory 1 (n = 783 men; n = 1143 women), "moderate-moderate increasing" trajectory 2 (n = 2794 men; n = 3266 women), "moderate high-moderate increasing" trajectory 3 (n = 1660 men; n = 1464 women), and "high-increasing" trajectory 4 (n = 341 men; n = 193 women). During the 3-year follow-up period, 840 (15.06%) men and 408 (6.72%) women developed MASLD, respectively. Compared with the trajectory 1 group, the trajectory 4 group had the highest risk (odds ration [OR] 2.99 [95% confidence interval {CI} 1.70, 5.24] for men; OR 2.37 [95% CI 1.04, 5.33] for women), followed by the trajectory 3 (OR 2.23 [95% CI 1.52, 3.30] for men; OR 2.37 [95% CI 1.45, 3.92] for women) and trajectory 2 (OR 1.43 [95% CI 1.07, 1.94] for men; OR 1.37 [95% CI 0.93, 2.03] for women) groups.ConclusionsHigh serum UA trajectories were independent risk factors for MASLD in both sexes, which is critical for informing prevention and treatment strategies in public health initiatives and clinical practice.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] Metabolic dysfunction-associated steatotic liver disease and cardiovascular risk factors in rheumatoid arthritis
    Saidi, A. N.
    Theel, W. B.
    Burggraaf, B.
    van der Lelij, A. J.
    Grobbee, D. E.
    van Zeben, J. D.
    van der Zwan-van Beek, E.
    Rauh, S. P.
    Cabezas, M. Castro
    CLINICAL RHEUMATOLOGY, 2025, : 1485 - 1492
  • [42] The plasma lipidome varies with the severity of metabolic dysfunction-associated steatotic liver disease
    Heymann, Clement J. F.
    Mak, Anne Linde
    Holleboom, Adriaan G.
    Verheij, Joanne
    Shiri-Sverdlov, Ronit
    van Mil, Saskia W. C.
    Tushuizen, Maarten E.
    Koek, Ger H.
    Grefhorst, Aldo
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [43] Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study
    Jeong, Seogsong
    Oh, Yun Hwan
    Ahn, Joseph C.
    Choi, Seulggie
    Park, Sun Jae
    Kim, Hye Jun
    Lee, Gyeongsil
    Son, Joung Sik
    Jang, Heejoon
    Lee, Dong Hyeon
    Sha, Meng
    Chen, Lei
    Kim, Won
    Park, Sang Min
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (03) : 487 - 499
  • [44] Active role of the immune system in metabolic dysfunction-associated steatotic liver disease
    Mori, Taizo
    Yoshio, Sachiyo
    Kakazu, Eiji
    Kanto, Tatsuya
    GASTROENTEROLOGY REPORT, 2024, 12
  • [45] Ethnic Minority Disparities in the Epidemiology of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Representative Area of China
    Ye, Jun Zhao
    Lin, Li Min
    Shao, Cong Xiang
    Mo, Sui Lin
    Ye, Miao Sheng
    Li, Xiao Yi
    Li, Qing
    Wang, Wen Geng
    Zheng, Qiao Cong
    Luo, Ke
    Zhang, Yi
    Tu, Shou Wei
    Che, Dai Tuan
    Gong, Ru Long
    Chen, Xing
    Miu, Rong
    Sun, Yan Hong
    Wu, Ting Feng
    Zhong, Bi Hui
    JOURNAL OF DIGESTIVE DISEASES, 2024, 25 (11-12) : 694 - 706
  • [46] Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in eastern China
    Ma, Guanghui
    Xu, Guohou
    Huang, Haixia
    DIABETOLOGY & METABOLIC SYNDROME, 2025, 17 (01)
  • [47] Lipotoxicity-driven metabolic dysfunction-associated steatotic liver disease (MASLD)
    Iturbe-Rey, Santiago
    Maccali, Claudia
    Arrese, Marco
    Aspichueta, Patricia
    Oliveira, Claudia P.
    Castro, Rui E.
    Lapitz, Ainhoa
    Izquierdo-Sanchez, Laura
    Bujanda, Luis
    Perugorria, Maria J.
    Banales, Jesus M.
    Rodrigues, Pedro M.
    ATHEROSCLEROSIS, 2025, 400
  • [48] Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease
    Long, Qichen
    Luo, Fengming
    Li, Binghui
    Li, Ziyang
    Guo, Zhe
    Chen, Zhiyang
    Wu, Weimin
    Hu, Min
    HEPATOLOGY COMMUNICATIONS, 2024, 8 (03)
  • [49] Gender difference in the association between serum uric acid and metabolic dysfunction-associated steatotic liver disease in patients with newly diagnosed type 2 diabetes
    Yuliang Cui
    Zhenzhen Qu
    Lingling Li
    Wenmei Hu
    BMC Gastroenterology, 25 (1)
  • [50] Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance
    Hutchison, Alan L.
    Tavaglione, Federica
    Romeo, Stefano
    Charlton, Michael
    JOURNAL OF HEPATOLOGY, 2023, 79 (06) : 1524 - 1541